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Abstract
Background: Family members are important companions of severely ill patients with cancer. However, studies
about the desirability and difficulties of integrating relatives in the decision-making process are rare in oncology.
This qualitative study explores the family role in decisions to limit treatment near the end of life from the professionals’
point of view.
Methods: Qualitative in-depth interviews were conducted with oncologists (n = 12) and nurses (n = 6) working at the
Department of Hematology/Oncology at the University Hospital in Munich, Germany. The data were analyzed using a
descriptive qualitative methodology and discussed from a medical ethics perspective.
Results: Four major themes played a central role in the perception of the medical staff in regard to family members.
(1) Family impact on patients’ treatment preferences. (2) Strong family wish for further treatment. (3) Emotional distress
of the family related to the involvement in end-of-life decision-making. (4) Importance of knowing family structures.
Conclusions: The important role of the family members in patients’ disease process is recognized by oncologists and
oncology nurses. However, this does not seem to lead to an early involvement of the family members. Developing and
establishing a systematic assessment of family members’ needs and wishes in order to provide a specific-tailored
support should become a priority for interdisciplinary clinical research in the near future.
Keywords: Medical oncology, Medical ethics, Communication, Palliative care, End-of-life decisions, Family
members, Qualitative research
Background
Family members are important companions and an irre-
placeable source of support for severely ill patients near
the end of life [1–8]. They provide emotional support
for patients and play a considerable role in patients’
choice of a treating oncologist, hospital, and in decisions
over possible treatment options. Furthermore, family can
facilitate or hinder a patient’s decision against further
cancer-specific treatment in favor of best supportive care
(BSC) with a focus on symptom control and quality-of-
life [9, 10].
A qualitative study with 37 patients with advanced
cancer and40 caregivers conducted by Zhang et al.
showed that 65% of families had disagreements regard-
ing treatment decisions including discontinuation of
anti-cancer treatment, thus considerably influencing pa-
tients’ treatment choices [11].
Empirical evidence demonstrates that patients place a
great importance on communication regarding treat-
ment options within their family [12]. In a study by
Schäfer et al. the majority (89%) of the surveyed onco-
logical patients preferred medical decisions to be made
jointly with their family and oncologists [13, 14]. In a
study by Hobbs et al. 49.4% of 5204 surveyed patients
with lung and colorectal cancer reported that they would
involve family members in decision making [15].
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In a cross-sectional interview study with 130 patients
who were diagnosed with incurable disease, Nolan et al.
showed that if patients were unable to decide for them-
selves in case of a severe illness, patients would feel
better if they could be represented by their relatives, ra-
ther than by their doctors [16].
It has also been shown, that family involvement in
decisions about forgoing treatment has positive effects
such as reducing patients’ distress and anxiety and in-
creasing their quality of life [17]. A study conducted
by Dionne-Odom et al. with 122 caregivers demon-
strated that family members who were integrated
quite early showed lower depression and distress
scores [18].
Additionally, timely involvement of family members
at different stages of decision-making process may help
family members to adjust to patients’ incurable disease,
to become more prepared for the approaching death
and to reduce their psychological distress [3, 19]. In
clinical practice, however, family members are often-
times involved in decision-making only to a small ex-
tent [20]. In a study on decision-making in the
Intensive Care Unit (ICU), Azoulay et al. showed that
even though the majority (91%) of physicians hold the
opinion that family members should be involved in
treatment decisions for patients without decision-
making capacity, only in one third of patients’ cases
family members were in fact involved in decision-
making [21]. It is a similar situation with patients who
are capable of making decisions: only in one-third of
patients’ cases family members were actually involved
in treatment decisions [2].
The previous research has mostly focused on a family
role in decisions regarding treatment options [22–27].
However, studies about the desirability and difficulties of
integrating relatives in the decision-making regarding
treatment limitations near the end of life and switching
to BSC from the professionals’ point of view are missing
in oncology, where patients are often capable of making
decisions to the end.
Therefore, we conducted a qualitative interview study
with oncologists and oncology nurses in order to gain
in-depth understanding of the family role in decision-
making for the specific context of a treatment limitation.
These interviews focus on forgoing cancer specific treat-
ment, but also touch on topics such as referral to ICU
and “Do not resuscitate order”. The focus of our study
was on the family role in decision- making when the
patient is able to communicate and make decisions. Our
aim was to identify and illuminate oncologists’ rationales
for and against family involvement as well as challenges
perceived by oncologists and oncology nurses while in-
volving family members in the decisional process of a
treatment limitation.
Methods
Study design and participants
A descriptive qualitative research approach - as
Sandelowski [28] described it - was used in order to get
information from oncologists and oncology nurses on
family involvement in decisions to limit treatment. This
methodological approach is especially suited to depict
precisely participants’ views and obtain answers to
research questions that are of a special relevance to in-
terviewees [28]. We aimed to provide a detailed descrip-
tion of oncologists’ and oncology nurses’ experience in
involving family in decision-making process on limiting
treatment near the end of life when patients are capable
to communicate.
Semi-structured qualitative interviews were conducted
with 18 participants in the Department of Internal
Medicine, which runs a comprehensive cancer center, at
the University of Munich Medical Center in Germany.
Sampling strategy and developing of the interview guide
We used a purposive sampling strategy to collect our
data. Selected participants were first contacted by email
with a detailed study description and were re-contacted
after 1 week by telephone and invited to participate in
the interview study.
For our first interviews we developed a preliminary
interview guide. It was developed in three steps: 1) in
the first step, review of the existing literature was con-
ducted; 2) in the second step, generated questions were
discussed in an interdisciplinary team meeting; 3) the
interview guide was discussed with the experts in oncol-
ogy and social sciences. It included open-ended
questions about end-of-life communication with
patients and family members and their role in
decision-making process.
The preliminary interview guide included such ques-
tions as:
 Tell me about your experience of decision-making
on treatment limitation by patients with advanced
cancer near the end of life;
 What role do the family play in these decisions?
 What is your opinion on family involvement in
decision-making to limit treatment near the end of life?
 What challenges do you face by family involvement
in decisions to limit treatment?
These questions served to start the conversation
and were followed up by going into more detailed
discussion.
After completing 8 interviews with oncologists and
analyzing our first data, more participants needed to be
selected to clarify the emerging themes.
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The interview guide was slightly modified and included
questions about the best way to involve relatives into
decision-making (i.e. What is the best way to integrate rel-
atives in decision-making to limit treatment? What factors
might hinder family involvement?). For this reason, we
approached oncologists with a special expertise in pallia-
tive care and in communication with family members.
Furthermore, we modified questions in order to inter-
view oncology nurses too as they could provide valuable
insight into relatives’ involvement and, according to
interviewed oncologists, often turned out to be a contact
person for families at the care unit. N6 interviews with
oncology nurses and with 4 oncologists were added to
the data.
A total of 18 participants – oncologists (4 male and 8 fe-
male, aged 30–65 years) and nurses (all female, aged
30-50 years) with different working experience and pos-
ition (fellows and seniors) were recruited. All participants
work at 4 general cancer wards caring for hematological
and oncological in-patients.
Interviews lasted for 30-100 min. Demographic data was
collected at the end of the interview. The demographic
characteristics of participants are presented in Table 1.
Memo-writing
During the whole research process, we wrote both
descriptive and reflective case-based memos on the
interviewing process, documented participants’ reactions
to the asked questions and also documented our emer-
ging new ideas during interviews. Data from the memos
were integrated into analysis.
Data analysis
Interviews were audiotaped, transcribed verbatim, and
analyzed according to the qualitative inductive content
analysis, including open coding, creating categories and
themes. In the first step of open codings, interview data
were analyzed “sentence by sentence”, segmented and
open codes were created. A code is understood as a
meaningful label for the text that expresses the data con-
tents. Through constant comparison, emerging codes
were connected by their similarities to categories.
The relationships between the categories were then
analyzed through constant comparison and linked into
themes.
As a last step, we explored an intercoder reliability in
order to judge the measurement consistency and to
achieve validation of the emerged codes. This means that
we tested the codes within three independent coders (KL,
EW, TP) which assigned the data with the same codes
[29]. Analysis was managed in using the data analysis soft-
ware MAXQDA (VERBI GmbH, Berlin, Germany).
The results were evaluated against the background of
the current medical ethics discussion on end-of-life
decision-making [30, 31].
Rigor
The following techniques were used to assess credibility,
transparency, analysability and usefulness of the data [32].
Credibility
The interviewer was not an employee of the hospital
where the study was conducted to guarantee neutrality.
However, the interviewer had experience in working
with oncological patients as well as expertise in qualita-
tive research methods. Researchers’ participation in in-
terviews and in data interpretation were constantly
reflected to reduce personal bias in research. For this
reason, field notes were written in which emerging
thoughts during the research process were documented.
Furthermore, regular interdisciplinary team meetings
served as a platform for reflection and acknowledgement
of researchers’ previous experience and background on a
theory development process.
Analysability
All interviews were digitally recorded, transcribed verba-
tim and checked by team members. After each interview
we wrote case-based memos that helped us to analyse
data. To increase analysability researcher triangulation
was used. Through regular meetings of the interdiscip-
linary team, with expertise in oncology, social science,
and medical ethics, multiple researchers were involved
in the analytical process. Emerging discrepancies of the
analysis were discussed in order to increase the validity
and reliability of the study.
Transparency
We discussed results in the context of current research
as well as limitations of the study and how they may im-
pact the results.
Table 1 Demographic characteristic of participants
Nurses 6
Male 0
Female 6
Age range 30-50 years old
Working experience range 12–20 years
Oncologists 12
Male 4
Female 8
Age range 30-65 years old
Working experience range 9 months to 16 years
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Usefulness
Interview participants were selected with a maximum
variance in working experience, positions and age in
order to increase the representatives of all aspects of the
topic in terms of participants [33]. For our research
question it was important to search for the maximum
variation in perspectives, ranging from the experienced
oncologists to nurses working at 4 hospital units.
Results
When asked about family role in decision-making to limit
treatment near the end of life, interviewed oncologists and
nurses often assigned an important role to patients’ family:
“I think, they play a very important role.” [Nurse 4] or
even as one nurse stated: “Sometimes, they play an even
more important role than the patient does” [Nurse 2].
Participants underlined the importance of families in
providing treatment advice to the patients: “I think, [they
play] an advisory role […]” “They just discuss it and see
what is the best.” [Nurse 4] as well as in providing support
and care for the patient throughout the disease.
However, they recognized that relatives often felt un-
prepared for end of life decision-making: “It is so, that
partly, relatives have not yet confronted themselves with
the situation, that has been known for a long time”
[Nurse 4], helpless or overwhelmed and needed psycho-
logical support when the patient was dying:
“Relatives cannot stand that you leave the room, and
when you are out of the room they start to call for
you, because they are uncertain and they are afraid.
They rather want that someone is there when he (the
patient) is on the verge or if he dies then.” [Nurse 3]
However, when asked about family involvement in
decisions, respondents commonly held the opinion that
relatives were for the most part not actively involved as
long as the patient was able to communicate. The inter-
viewees made it clear that their first choice and contact
was always the patient who was capable of making deci-
sions: “The priority in my decision-making has always
been the patient as long as he is in full position of emo-
tional and mental force. I listen to what relatives say
always merely as a secondary opinion” [Physician 8].
When asked about what was the best way to integrate
family members in decision-making, some oncologists
saw the necessity to prepare family members slowly for
the approaching situation of a patient’s death and sug-
gested that it would be important to create a “humane
environment” [Physician 10] and involve family mem-
bers step by step in the end of life decision-making: “[...]
That you not only have the conversation with the patient
and family members together, but also that you discuss
it with the family-members to prepare them for the situ-
ation.” [Physician 3].
Relatives were often compared by oncologists and
nurses with second patients. They were perceived not
only as patients’ informants and supporters but also as
affected by a crisis situation due to a life-threatening
disease of their beloved one. Therefore, they needed to
be taken care of too. “Also, from the side of physicians
and I think from the side of nurses it is important to
take care of relatives just like of patients, like a sick
person” [Nurse 3].
However, they pointed out some several important as-
pects that should be taken into consideration when in-
volving family and that might even hinder the family
involvement in decision-making: 1) family impact on pa-
tients’ treatment preferences; 2) a strong family wish for
further treatment; 3) emotional distress of the family
related to the involvement in end-of-life decision-
making; 4) importance of knowing family structures.
These aspects are presented below with appropriate
participants’ citations.
Family impact on patients’ treatment preferences
Oncologists and nurses reported that family oftentimes
served as an important advisor for the patient regarding
treatment options and that their impact on patients’
preferences might be underestimated:
“Uh, we probably underestimate this a little, because
[…] the process of discussion goes on even further at
home with the family, which of course has an impact
on patients.” [Physician 10]
Interviewees also noticed, that patients might strive
for a life-prolonging treatment for the sake of the family:
“Well, I think relatives and the whole family have a
significant impact. So, I guess, if there is an intact
family, the patient just wants everything to be done to
have simply more time with his family [...].” “But
especially we experience it again and again with young
families, where patients do everything only in order to
think that they have maybe one chance more to
survive.” [Nurse 5]
Patients could be pressured or coerced by their fam-
ilies into making medical decisions that are not in line
with their wishes.
Strong family wish for further treatment
When asked about challenging situations in discussing
treatment limitations with family members, a situation
that was often perceived as challenging by oncologists
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and nurses was when family members could not accept
patients’ situation:
“Relatives just cannot support it or accept that patient
does not want to have it [treatment] now.” [Nurse 4]
In such cases relatives demanded a more intensive
treatment than the medical team would support:
“Well, […] but there are always cases where relatives
just come up to you and say, that everything should
be done.” [Physician 2]
In a case of very demanding family members oncolo-
gists involved family in decision-making to protect
themselves from possible legal consequences. They
admitted that they would seek a conversation with pa-
tients’ family even if they had already decided upon
treatment limitations in order to prevent any legal action
from the family side:
“And of course, for the reason that you want to
protect yourself from legal actions, I admit that
openly. Frequently, I think if we say that he will not
be resuscitated or he’ll not go to the ICU in case of
deterioration: these are often things that you might
medically justify, however you also protect yourself
legally and you do that better together with family
members.” [ Physician 10]
So, a patient’s wish for further aggressive treatment
and unwillingness to talk about indicated therapy limita-
tion near the end of life can be rooted in family un-
readiness of accepting the patient’s situation, resulting in
a strong preference for life-prolonging treatment.
Emotional distress of the family related to the
involvement in end-of-life decision-making
An important concern expressed by oncologists and
nurses about the family involvement in treatment deci-
sions was that it might overburden them, causing emo-
tional distress, anxiety and depression.:
“I think that relatives are completely overburdened to
make such decisions…” [Physician 12], “I think, in
general, relatives are shocked even if you prepare
them for this […] so that they say do as you consider
right…” [Physician 3].
Oncologists deliberately avoided putting family mem-
bers in the position to decide about treatment intensity
since this might generate a psychological burden on
them. They also reported that relatives’ emotional
proximity to the patient often did not allow them to
decide objectively:
“Yes, I think that the family members virtually play a
very minor role because relatives would take the
initiative and say, he (the patient) shall die now, yes, or
we stop now [treatment]…. I think relatives are more
likely to cling to the patient like crazy [...] So, I think
that family members are completely overwhelmed uh,
to make such decisions.” [Physician 12]
Importance of knowing family structures
Study participants reported that for family involvement
in decision-making to limit treatment it is important to
know about family structures and interpersonal relation-
ship within a patient’s family: “When the patient is able
to make decisions, then, it depends how good the rela-
tionship was” [Nurse 4].
And it becomes especially important when patients
lose their decisional capacity:
“It depends on how good they understood each
other in normal life.” [Nurse 4], “[Family members]
I would definitely involve them, yes, and especially
if someone is not doing well and can no longer
express his will. Yes, but I find that very
questionable, when I do not know the family
environment.” […] [Physician 4].
When a patient loses his decision-making capacity, the
family becomes more involved in the decision-making
process as informants about patients’ preferences:
“Um, it's often the case that patients are so weak in
this last phase, and no longer have this capacity to
decide one hundred percent for themselves how
things should be done and then family members play
a bigger role.” [Physician 1]
However, participants admitted that it was important
to know patients’ family and to determine relatives’ rela-
tionship to the patient in order to interpret the agenda
put forward by the relatives:
“I think the patient is more important, because there
are always situations when the family members
pursue certain purposes, yes. But it also depends on
how well you know the family situation.” [Physician 4]
All participants acknowledge the importance of know-
ing family structures, especially by patients who have a
limited decision-making capacity.
Laryionava et al. BMC Palliative Care  (2018) 17:29 Page 5 of 9
Discussion
The statements of the interviewed oncologists and
nurses made it clear that they acknowledged the pres-
ence of family members and valued their emotional sup-
port for patients. However, relatives were also often
perceived as second patients who could be traumatized
by a patient’s situation and needed special attention, care
and time investment.
Participants in our interview study, reported that fam-
ily members were mostly not involved as long as the pa-
tient had the capacity to make decisions; rather, they
were seen as informants on patients’ will for incapaci-
tated patients. This corresponds with the legal require-
ment that involved relatives should not express their
own preferences, but should represent and adhere to
patients’ authentic wishes and values. According to the
patient care legislation in Germany relatives need to be
officially designated as a proxy decision-maker either by
the patient through an advanced directive or by the
court in order to decide on behalf of the patients
(§1901a.1 of the German Civil Code (Bürgerliches
Gesetzbuch, BGB) [34, 35].
We could identify four certain barriers that might
hinder a successful family involvement in end of life
decision-making: 1) family impact on patients’ treatment
preferences; 2) strong family wish for further treatment;
3) emotional distress of the family related to the involve-
ment in end-of-life decision-making; 4) importance of
knowing family structures.
We will discuss them here against the background of
the literature and the debate in medical ethics.
Family impact on patients’ treatment preferences
For the surveyed oncologists and nurses, family mem-
bers did exert a certain “influence” on patients’ prefer-
ences regarding treatment choices. This is in line with
other studies. Grunfeld [36] could show i.e. that in up to
28% of patients with breast cancer their relatives were
even a key influencing factor in treatment decisions. The
interviewees observed in patients with strong family re-
lations an especial a preference for exhausting treatment
options in order to gain life-time. This resonates well
with our past research that showed that family influence
was associated with patients’ striving more for length of
life rather than quality of life [37].
Therefore, involving family members in treatment,
planning early on, providing them with more informa-
tion regarding patients’ prognosis and treatment options,
could help them to create a realistic view of patients’
situation. Thus, families can even facilitate a transition
to the best supportive care. Most patients and families
want to discuss forgoing aggressive treatment and the
transition to best supportive care with their oncologists
and feel frustrated when such discussions do not happen
in a timely manner [8].
Family wish for further treatment
According to the results of our study, family members
were occasionally perceived by participants as very
demanding if they challenged professional decisions or
tried to exert too much influence on medical practice
and on the patients. Patients with close family contacts
might be prone to life-prolonging treatment in order to
comply with family preferences, especially if their rela-
tives insist on further aggressive treatment and deny a
patient’s poor prognosis. Hence, there might be a higher
risk of disagreement and collusion between relatives and
oncologists in decision-making about treatment limita-
tions. It therefore seems absolutely reasonable to involve
patients and their relatives early on and to address their
treatment expectations in order to prevent situations of
disagreement and consecutive ethical and legal conflicts
[38]. If family members get the chance to witness the de-
clining effectiveness of therapeutic efforts when the
disease is progressing, they can develop a better under-
standing of the medical complexity and of a limited
prognosis of the disease. Studies show that in fact, as pa-
tients’ diseases progress, families become more accepting
of sharing difficult treatment decisions with the patient
and oncologists [39].
In case of very demanding family members some
oncologists mention the fear of a legal dispute when they
do not comply with the wishes of family members, e.g.
when family members request continuation of futile
therapy. In that scenario oncologists try to protect them-
selves from legal action through engaging relatives in
proactive conversations.
Emotional distress of the family related to the involvement
in end-of-life decision-making
The interviewees of our study expressed their desire to
involve family members, but they also acknowledge that
family might suffer from anxiety and depression some-
times even to a greater degree than the patient himself.
Many studies show that family members do suffer
from stress, anxiety, fatigue and depression [40–45].
Thus, family members can be hesitant to any involve-
ment in decision-making. In a study by Azoulay et al.
half of the family members did not want to participate
in treatment decisions about intensive care measures
[21]. Others even question the decision-making ability of
caregivers in the intensive care setting altogether and
doubt the usefulness of involving the partly frightened
and traumatised family in the decision-making process
at all [46]. For family members of cancer patients, it has
been shown that they have unmet needs for support,
mainly with regard to fears concerning patients’
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condition. Furthermore, they wish to receive a disease-
related information and want emotional support for
themselves [47]. Family members of cancer patients who
were integrated quite early on demonstrated lower de-
pression and distress scores [18]. Hence, family members
should be integrated in the decision-making process
early on and not only if patients’ condition has worsened
in the acute care setting or when end of life decisions
have to be made [48, 49]. Furthermore, family members
should be perceived as a separate unit from patients with
their own needs and wishes as these can considerably
differ from that of a patient. Relatives should be offered
counselling for social and financial questions and psy-
chological support [50, 51].
Importance of knowing family structures
In cases of incapacitated patients who cannot express
their wishes our interviewed oncologists felt rather un-
confident to involve family members, if they did not
know them well. This approach is in accordance with a
patient care legislation in Germany and the instrument
of advanced directives as have been mentioned early in
this paper.
Just as the implementation of advanced directives at
the beginning of care seemed quite promising as a
source for the patients will further clinical practice could
show that physicians commonly rely on the family mem-
bers as substitute decision makers in incapacitated
patients [35, 52]. In clinical practice, physicians are often
consulted either to interpret the meaning of preferences
expressed in patients’ advanced directive or to explore
patients’ presumed preferences if no written advanced
directive exists. Here, an early contact and exploration
of the important decision makers in the family could
help oncologists to gain more insight into family matters
and potentially conflicting perspectives regarding treat-
ment goals. Insights like these might help oncologists to
build consensus between patients and relatives in case of
a disagreement. Moreover, any statement of relatives –
especially when the patient cannot communicate
anymore – need to be understood well against the back-
ground of their context, which is often unclear to the
observer and, thus, require interpretation. We could not
find any existing research which covers this new aspect.
Limitations of the study
One limitation of this study was that we could not re-
turn the interpreted data to participants to check for ac-
curacy and to see if themes were worked out adequately
and reflect the participants’ experience due to the lack
of time resources of oncologists and nurses.
Our findings are not necessarily transferrable to other
care settings. We searched for a maximum variation in
our sampling in order to increase the transferability. Our
interviews were conducted in a big university hospital
that is characterized through a high staff rotation and a
considerable time pressure on oncologists and nurses.
So, the results might be representative only for univer-
sity hospitals.
In order to generalize these findings to all hospital
settings further quantitative, and complementary qualita-
tive research involving other hospitals and geographic
settings is required.
Hence, this qualitative study is a first step towards an
understanding of family involvement in decision-making
to limit treatment near the end of life and more needs to
be done (i.e. investigating different settings, using differ-
ent research methods) to get a deeper insight into such
a complex phenomenon.
Conclusion
The findings of our study address the existing gap in
the literature on the role of patients’ family in decision-
making to limit treatment near the end of life when
patients are able to make decisions and to communi-
cate with their oncologists and nurses. Although, par-
ticipants recognised the important role of the family in
decision-making, they also acknowledged certain chal-
lenges such as possible psychological burden of the
relatives, the challenge of knowing family structures,
and a strong family wish for further treatment that
would seem to account for the reluctance of oncologists
for a proactive position regarding family involvement in
decision-making.
Strong reasons exist for involving patients’ family early
on (if patient authorisation of family involvement is pro-
vided) in order to help them to cope with the situation
as well as to empower and prepare them for the task to
act as surrogates and co-helpers. Not only is early
involvement of relatives often in accordance with patient
preferences; it also allows for a better understanding of
eventual disagreement regarding treatment decisions.
Moreover, early integration could assist family members
to gain a better grasp of futile therapy situations so that
they might be less inclined to insist on non-beneficial
anti-cancer treatment or life-sustaining measures for
their dying loved-one [48]. The inclusion of additional
consultation services such as clinical ethics, pastoral
care, psycho-oncology, and clinical social service to-
gether with the family, might offer patients and relatives
an important aid in processing and mastering disease-
specific problems. However, some requirements need to
be implemented before early integration is initiated:
obtaining the approval for family involvement by the pa-
tient, and developing and establishing a systematic
assessment of family members’ needs and their wishes in
order to provide specific-tailored support.
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